The 14 most recent market catalysts affecting $BAYN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 55
Berenberg Updates Price Target and Estimates for Bayer
Berenberg, a prominent financial institution, has revised its price target and financial estimates for Bayer AG. This update is driven by an observed growth and momentum within Bay…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 55
Bayer Announces Strategic Healthcare and Agricultural Initiatives in Asia-Pacific
Bayer announced strategic initiatives in the Asia-Pacific region, focusing on healthcare and agriculture. In healthcare, the company is addressing the burden of an aging population…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Research Raises Bayer Price Target to 65 Euro
Deutsche Bank Research raised Bayer's price target to 65 Euro from 60 Euro, while reiterating a 'Buy' rating. This positive revision stems from updated financial estimates for 2027…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Bayer Consumer Health China Partners with Sirio Pharma for Evidence-Based Research
Bayer Consumer Health China is partnering with Sirio Pharma to create a joint research laboratory for evidence-based nutrition. This initiative is significant as it signals Bayer's…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Bayer Consumer Health Announces Strategic Partnerships and Joint Laboratory at CIIE
Bayer Consumer Health is strategically expanding its presence in the lucrative Chinese market through new distribution partnerships with Jiuzhoutong, Ruoyuchen, and Shanghai Pharma…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Adjusts Bayer Price Target Following Q3 Results
Jefferies increased its price target for Bayer to 48.50 euros from 46 euros after the company's third-quarter financial results. Despite the price target increase, the firm maintai…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 85
Bayer Updates Financial Outlook and Debt Reduction Targets
Bayer AG announced an improved financial outlook, specifically raising its cash flow forecast and lowering its year-end debt target by 1 billion euros to 28-29 billion euros. This …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
Bayer Launches New Biologicals Brand in Latin America
Bayer has launched 'Biológicos Bayer,' a new brand aimed at significantly expanding its biologicals portfolio in Latin America, with 17 new products planned by 2030. This initiativ…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
Bayer to Present New Cardiovascular, Kidney, and Stroke Data at 2026 AHA Scientific Sessions
Bayer is announcing its participation in the 2026 AHA Scientific Sessions, where it will present new data from its cardiovascular, kidney, and stroke portfolios. The key highlight …
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Bayer Enters Commercialization Agreement with HLS Therapeutics for VERQUVO® in Canada
Bayer has signed a commercialization agreement with HLS Therapeutics for its heart failure drug VERQUVO® in Canada, with HLS taking over commercial and medical education activities…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 85
Bayer Reports Unexpected Q3 Earnings Growth Driven by Pharmaceuticals
Bayer reported an unexpected rise in Q3 operating results, primarily due to a significant recovery and strong growth in its pharmaceutical business. This positive performance is cr…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 75
Bayer Receives First Global Approval for Stroke-Prevention Drug Sunharbo in China
Bayer has secured the first global approval for its Factor XIa inhibitor, Sunharbo, in China for stroke prevention. This is a significant corporate catalyst as it marks the success…
Oct 24, 2026
Corporate Catalyst
Bullish
Impact 75
Bayer Reports Positive Phase III Results for NUBEQA® in Prostate Cancer Patients
Bayer reported highly positive Phase III clinical trial results for NUBEQA® (darolutamide) in combination therapy for high-risk localized prostate cancer, demonstrating a 58% reduc…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Bayer Partners with Phylo to Enhance Scientific Evidence Assembly
Bayer has announced a partnership with Phylo, gaining full access to Phylo's agentic platform. This platform is designed to integrate scientific literature, biomedical data, and an…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.